T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape

Bispecific chimeric antigen receptor T-cell (CAR-T) therapies have shown promising results in clinical trials for advanced B-cell malignancies. However, it is challenging to broaden the success of bispecific CAR-T therapies to treat refractory/relapse (r/r) T-cell leukemia/lymphoma because targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Zhenyu, Mu, Wei, Zhao, Ya, Cheng, Jiali, Lin, Haolong, Ouyang, Kedong, Jia, Xiangyin, Liu, Jianwei, Wei, Qiaoe, Wang, Meng, Liu, Chaohong, Tan, Taochao, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948246/
https://www.ncbi.nlm.nih.gov/pubmed/35332132
http://dx.doi.org/10.1038/s41392-022-00898-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948246/
https://www.ncbi.nlm.nih.gov/pubmed/35332132
http://dx.doi.org/10.1038/s41392-022-00898-z

Ejemplares similares